Почетна › Лимфом › Masachuset › Boston
Kliničke studije za Лимфом u gradu Boston, MA
34 studija za Лимфом traži učesnike na lokacijama u gradu Boston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Тражи се учесникФаза 1/2
- Call for Information (Investigational Site 0026), Boston
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Тражи се учесникФаза 3
- Tufts Medical Center, Boston
HEME Home Transfusion Program
Тражи се учесник
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Тражи се учесник
- Mass General Hospital, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Тражи се учесникФаза 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
Тражи се учесникФаза 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Тражи се учесникФаза 1/2
- Research Site, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Тражи се учесникФаза 3
- Research Site, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center - Research, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Тражи се учесник
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Тражи се учесникФаза 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Тражи се учесникФаза 2
- Dana Farber Cancer Institute, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Тражи се учесникФаза 1/2
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Тражи се учесникОпсервациона студија
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
Тражи се учесник
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Тражи се учесник
- Massachusetts General Hospital Cancer Center, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Тражи се учесник
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute, Boston
Odronextamab in Low Tumor Volume Advanced FL
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Тражи се учесник
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
Тражи се учесникФаза 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Тражи се учесникФаза 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Тражи се учесникФаза 2
- Dana Farber Cancer Institute, Boston
Studije za Лимфом u drugim gradovima
- Houston, TX34 студија
- New York City, NY33 студија
- Washington, DC23 студија
- Baldwin Park, CA22 студија
- Chicago, IL19 студија
- Durham, NC17 студија
- St. Louis, MO15 студија
- Cleveland, OH13 студија
- Seattle, WA13 студија
- Atlanta, GA13 студија
- Philadelphia, PA13 студија
- Edison, NJ12 студија
Ostale studije u gradu Boston
- Рак дојке110 студија
- Рак (све врсте)90 студија
- Немалоклетни карцином плућа87 студија
- Рак плућа63 студија
- Колоректални карцином62 студија
- Рак јајника62 студија
- Метастатски карцином61 студија
- Рак простате56 студија
- Карцином ендометријума51 студија
- Депресија50 студија
- Затајење срца46 студија
- Многи мијелом45 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.